Episode 4, series 1. How I treat triple negative early breast cancer and those with genetic predisposition

In this episode Dr Jenner, breast cancer specialist in Bristol, discusses two areas. Firstly the use of adjuvant chemotherapy in a person with triple negative early breast cancer. Secondly she discusses who should be referred for genetic screening and, if positive, what should be offered to them and their family.

The Bristol Oncology Podcasts

How I treat triple negative early breast cancer and impact of genetic risk factors

Triple negative breast cancer: current perspectives on the evolving therapeutic landscape
Mehanna et al
Int J Womens Health 2019 11 431-7

Overview paper

The treatment and survival of patients with triple negative breast cancer in a London population
Pal et al
Springerplus 2014 3 553

paper demonstrating the reduced survival of those with triple negative breast cancer

Clinicopathologic features, patterns of recurrence and survival amongst women with triple negative breast cancer in the NCCN
Lin et al
Cancer 2012 118(22): 5463-72

Another overview of the survival

Increasing the dose intensity of chemotherapy by more frequent administration or sequential scheduling: a patient-level meta-analysis of 37298 women with early breast cancer in 26 randomised trials
Lancet 2019 393 (10179) 1440-52

Dose dense chemotherapy

Platinum based new-adjuvant chemotherapy in triple negative breast cancer: a systemic review and meta-analysis
Poggio et al
Ann Oncol 2018 29(7) 1497-1508

Use of platinum chemotherapy

Adjuvant capcitebine for breast cancer after preoperative chemotherapy
Masuda et al
NEJM 2017 376(22) 2147-59

Familial breast cancer: classification, care and managing breast cancer and related risks in people with a family history of breast cancer

View Online
Estimates of the likely prophylactic effect of tamoxifen in women with high risk BRCA1 and BRCA2 mutations
Duffy et al
Br J Cancer 2002 jan 21 86(2) 218-221